Related Experiment Videos
Clinical value of microalbuminuria in hypertension
1Department of Internal Medicine (Nephrology), University of Brasilia, Brazil.
Abstract:
Microalbuminuria (MA) is a well recognized marker of cardiovascular complications in hypertension, but whether MA can predict adverse outcome in this clinical condition is still a subject for debate. The fact that in hypertensive cohorts those patients who showed an increase in albumin excretion rate also manifested an increased incidence of morbid events indicates that the presence of MA in hypertension may carry an increased cardiovascular risk. However, the prognostic significance of MA remains controversial because no results of prospective studies performed in hypertensive subjects without diabetes mellitus are available. Several factors can affect the prevalence of MA in hypertension, including severity of the disease, selection procedures, concomitant risk factors, degree of obesity, age, and sex distribution. This accounts for the large differences in the prevalence of MA that can be found in the literature, with prevalence rates going from a low of 4.7% to a high of 40%. There is still conflict over whether MA in hypertension is due to increased intraglomerular pressure or to glomerular damage. The data from the literature suggest that in subjects with mild hypertension the main determinant of albumin excretion rate is the haemodynamic load. In subjects with more severe hypertension and hypertensive complications, the augmented urinary albumin leak is probably the consequence of a systemic microvascular disturbance which involves the glomeruli. In this respect, the insulin resistance state often associated to high blood pressure appears as one of the main pathogenetic factors. Whether management of hypertensive populations may be improved by monitoring of albumin excretion rate and whether antihypertensive drugs which are more effective in decreasing urinary albumin can be more beneficial in patients with MA remains to be determined.
Insights
Microalbuminuria (MA) indicates increased cardiovascular risk in hypertension patients. Further prospective studies are needed to confirm its prognostic significance in non-diabetic hypertensive individuals.
Area of Science:
- Nephrology
- Cardiology
- Hypertension Research
Background:
- Microalbuminuria (MA) is a recognized marker for cardiovascular complications in hypertension.
- Its prognostic significance in predicting adverse outcomes in hypertensive patients, particularly those without diabetes, remains debated.
- Prevalence rates of MA in hypertension vary widely (4.7% to 40%) due to factors like disease severity, obesity, and age.
Purpose of the Study:
- To investigate the prognostic significance of microalbuminuria in hypertensive individuals without diabetes mellitus.
- To explore the underlying mechanisms of albuminuria in hypertension, differentiating between hemodynamic load and glomerular damage.
- To assess the potential benefits of monitoring albumin excretion rate and specific antihypertensive drugs in managing hypertensive populations with MA.
Main Methods:
- Review of existing literature on microalbuminuria in hypertensive cohorts.
- Analysis of factors influencing MA prevalence, including disease severity and risk factors.
- Discussion of proposed pathogenetic mechanisms, such as intraglomerular pressure, glomerular damage, and insulin resistance.
Main Results:
- Hypertensive patients with increased albumin excretion rates show a higher incidence of morbid events, suggesting increased cardiovascular risk.
- In mild hypertension, hemodynamic load is a primary determinant of albumin excretion.
- In severe hypertension, augmented albuminuria may result from systemic microvascular disturbances, potentially linked to insulin resistance.
Conclusions:
- The prognostic value of MA in hypertension requires further validation through prospective studies in non-diabetic populations.
- Understanding the interplay between hypertension, MA, and conditions like insulin resistance is crucial for risk stratification.
- Further research is needed to determine if monitoring MA and using specific antihypertensive agents can improve patient outcomes.